Welcome to PsorVal.net | DermaSolve.net !


Your Source for Psor-Val | DermaSolve | Absorbase


 Serving Treatment Solutions for Psoriasis, Eczema, Dry Skin 


Providing News, Views, Tips and Tricks

along with great products for that   "Healthy You" 


Looking for Psor-Val Spray? Click here 

*Buy Psor-Val on Amazon* Click here


Now Shipping Psor-Val Spray World Wide

 International Clients - Click "We Ship Worldwide!"

MedWorm: Psoriasis

Arsenic trioxide-based therapy is suitable for patients with psoriasis-associated acute promyelocytic leukemia - A retrospective clinical study. (Sun, 14 Feb 2016)
Conclusions Psoriasis patients are at high risk for APL. The increased risk is most likely associated with the genetic background and bimolane treatment. The ATO-based therapy is especially suitable for patients with psoriasis-associated APL. Our study also brings a new treatment option for psoriasis. PMID: 26871996 [PubMed - as supplied by publisher] (Source: Hematology) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
>> read more

Highlighting Kathleen Green and Mario Delmar, guest editors of special issue (part 2): junctional targets of skin and heart disease. (Sat, 13 Feb 2016)
Authors: Cowin P Abstract Cell Communication and Adhesion has been fortunate to enlist two pioneers of epidermal and cardiac cell junctions, Kathleen Green and Mario Delmar, as Guest Editors of a two part series on junctional targets of skin and heart disease. Part 2 of this series begins with an overview from Dipal Patel and Kathy Green comparing epidermal desmosomes to cardiac area composita junctions, and surveying the pathogenic mechanisms resulting from mutations in their components in heart disease. This is followed by a review from David Kelsell on the role of desmosomal mutation in inherited syndromes involving skin fragility. Agnieszka Kobeliak discusses how structural deficits in the epidermal barrier intersect with the NFkB signaling pathway to induce inflammatory diseas...
>> read more

Junctions and inflammation in the skin. (Sat, 13 Feb 2016)
Authors: Kobielak A, Boddupally K Abstract The skin forms a life-sustaining barrier between the organism and physical environment. The physical barrier of skin is mainly localized in the stratum corneum (SC); however, nucleated epidermis also contributes to the barrier through tight, gap, and adherens junctions (AJs), as well as through desmosomes and cytoskeletal elements. Many inflammatory diseases, such as atopic dermatitis (AD) and psoriasis, are associated with barrier dysfunction. It is becoming increasingly clear that the skin barrier function is not only affected by inflammatory signals but that defects in structural components of the barrier may be the initiating event for inflammatory diseases. This view is supported by findings that mutations in filaggrin, a key structur...
>> read more

Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis. (Sat, 13 Feb 2016)
Authors: Wong IT, Shojania K, Dutz J, Tsao NW Abstract Secukinumab represents the first IL-17A antagonist among the available biologic therapies approved for moderate-to-severe plaque psoriasis management. Secukinumab demonstrated greater efficacy over placebo, etanercept and ustekinumab in patients that had limited benefit from non-biologic systemic therapies and phototherapy. Despite standard-of-care systemic therapies being more likely to be cost-effective at this time, a Canadian cost-utility analysis found secukinumab to display benefit in quality-of-life gains in moderate-to-severe plaque psoriasis patients, and greater cost-effectiveness when compared to other biologic systemic therapies. Determination of the true economic value of secukinumab amongst the available therapies...
>> read more

The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. (Sat, 13 Feb 2016)
Authors: Rouse NC, Farhangian ME, Wehausen B, Feldman SR Abstract Given its chronicity and impact on quality of life, psoriasis is a costly disease. As new and better treatments are developed, the cost of treating psoriasis has risen. In this drug profile, the authors discuss ustekinumab, its pharmacokinetics, safety profile, and direct and indirect costs to determine its cost-efficacy. The authors searched PubMed with specific search phrases for clinical trials investigating this issue over 5 years. Eleven articles analyzed cost-effectiveness of ustekinumab, and the references of these articles were included. Studies limited to 12 weeks reported that ustekinumab may not be cost-effective as it has high cost per injection and is costly when loading doses are required. Studies tha...
>> read more

Indirect costs of absenteeism due to rheumatoid arthritis, psoriasis, multiple sclerosis, insulin-dependent diabetes mellitus, and ulcerative colitis in 2012: a study based on real-life data from the Social Insurance Institution in Poland. (Sat, 13 Feb 2016)
CONCLUSIONS: Considering only data on absenteeism collected by the Social Insurance Institution in Poland, we can conclude that the selected autoimmune diseases are associated with great indirect costs. PMID: 26377953 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
>> read more

Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. (Sat, 13 Feb 2016)
CONCLUSIONS: Infliximab has higher cost to the VHA than adalimumab or etanercept. PMID: 26337538 [PubMed - in process] (Source: Journal of Medical Economics)
>> read more

Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis (Thu, 11 Feb 2016)
Publication date: 1 May 2016 Source:Colloids and Surfaces B: Biointerfaces, Volume 141 Author(s): Hagar Bessar, Iole Venditti, Luisa Benassi, Cristina Vaschieri, Paola Azzoni, Giovanni Pellacani, Cristina Magnoni, Elisabetta Botti, Viviana Casagrande, Massimo Federici, Antonio Costanzo, Laura Fontana, Giovanna Testa, Fawzia Farag Mostafa, Samia Ali Ibrahim, Maria Vittoria Russo, Ilaria Fratoddi Gold nanoparticles (AuNPs) represent an effective choice for topical drug delivery systems thanks to their small size, general non-toxicity, ease of functionalization and high surface to volume ratio. Even if systemic, methotrexate still plays an important role in psoriasis treatment: its topical use shows insufficient percutaneus penetration owing to limited passive diffusion, hi...
>> read more

Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series (Thu, 11 Feb 2016)
ConclusionAlthough sample size and study design limit the data from this study, the study provides some guidance where little exists and helps to support the use of these treatments in this setting. (Source: Pediatric Dermatology)
>> read more

A biosimilarity index for psoriasis (Thu, 11 Feb 2016)
Linked Article: Blauvelt, et al. Br J Dermatol 2016; 174: 282–286. (Source: British Journal of Dermatology)
>> read more


Scan our QR Code to your Smart Phone / iPhone Users download QR Reader from Tap Media http://www.TapMedia.co.uk 

Real Time Web Analytics

International Clients, After adding products to Cart - Refresh your browser if you do not see the "International Checkout" Button

Psor-Val Zinc Spray, DermaSolve Psoriasis Care Products and

Absorbase Cream for Moisturizing Skin Care.


Treatment Solutions and Products for Psoriasis, Eczema, Dry Skin. Natural Care for that Healthy You!